Next Article in Journal
Enhanced Sensing Performance of Integrated Gas Sensor Devices
Previous Article in Journal
Thermoelectric Microsensor Based on Ultrathin Si Films
Article Menu
Issue 25 (Cell Death 2018) cover image

Article Versions

Export Article

Open AccessProceedings
Proceedings 2018, 2(25), 1573; https://doi.org/10.3390/proceedings2251573

Anti-Cancer Acitivity of Etodolac and Its Derivatives on Prostate and Colorectal Cancer Cell Lines

1
School of Medicine, Department of Biophysics, Maltepe, Marmara University, 34854 Istanbul, Turkey
2
School of Pharmacy, Department of Pharmaceutical Chemistry, Marmara University, Haydarpasa, 34668 Istanbul, Turkey
Presented at the 2nd International Cell Death Research Congress, Izmir, Turkey, 1–4 November 2018.
*
Author to whom correspondence should be addressed.
Published: 7 December 2018
PDF [607 KB, uploaded 7 December 2018]

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used as anti-inflammatory and analgesic agents. This family of drugs suppresses prostaglandin synthesis through inhibition of cyclooxygenase (COX) enzymes. Recent studies showed that anti-carcinogenic effects of these drugs are especially mediated by COX-2 enzyme. Etodolac is a COX-2 inhibitor and though not perfectly selective, it exhibits “preferential selectivity” for COX-2. In this study, the anti-proliferative and apoptotic effects of etodolac and its hydrazone or triazole derivatives (SGK 206 and SGK 242, respectively), were investigated on prostate cancer cell line PC-3 and human colorectal carcinoma cell line HT-29. Our data showed that SGK 206 and SGK 242 were more effective in the inhibition of proliferation and induction of apoptosis compared to etodolac in both cell lines.
Keywords: PC-3; HT-29; etodolac; cancer; apoptosis PC-3; HT-29; etodolac; cancer; apoptosis
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Sevinç, S.K.; Orun, O.; Tiber, P.M.; Çıkla-Süzgün, P.; Küçükgüzel, Ş.G. Anti-Cancer Acitivity of Etodolac and Its Derivatives on Prostate and Colorectal Cancer Cell Lines. Proceedings 2018, 2, 1573.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Proceedings EISSN 2504-3900 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top